X

Drug Profile

YNP 1707

Alternative Names: YNP1707

Latest Information Update: 28 Feb 2019

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Yungjin Pharm Co
Class Analgesics; Anti-inflammatories
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

No development reported Neuropathic pain

Most Recent Events

28 Feb 2019 No recent reports of development identified for phase-I development in Neuropathic-pain in South Korea (PO, Tablet)
21 Jan 2016 Phase-I clinical trials in Neuropathic pain in South Korea (unspecified route) prior to January 2016 (Yungjin Pharm's pipeline, January 2016)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com